相关实验视频

Updated: May 5, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

通过阻断腺A2A受体来增强肝细胞癌的化学栓塞的免疫激活的微球

Minjiang Chen¹, Yaning Chen², Weiqian Chen³

¹Zhejiang Key Laboratory of Imaging and Interventional Medicine, School of Medicine, Lishui Hospital of Zhejiang University, Zhejiang, China; Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, The Fifth Affiliated Hospital of Wenzhou Medical University, Zhejiang, China; Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang, China.

Acta biomaterialia

|April 24, 2025

概括

这项研究开发了新的微球,以改善肝癌 (HCC) 的透管动脉化学栓塞 (TACE). 该疗法增强癌细胞死亡,并通过阻断腺素通路来增强抗瘤免疫力,改善TACE的疗效.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物医学工程生物医学工程

背景情况:

过导管动脉化学栓塞 (TACE) 是对不可切除的肝细胞癌 (HCC) 的首要治疗方法.
TACE诱导癌细胞死亡,但也触发了腺 (ADO) 途径免疫抑制,限制了它的有效性.
腺二甲受体 (A2AR) 信号通路是这种免疫抑制的关键媒介,阻碍免疫细胞死亡 (ICD).

研究的目的:

开发一种新的治疗策略,以克服腺介导的免疫抑制,并提高TACE在HCC治疗中的疗效.
为了创建双重负载的微球,封装多克索鲁比 (DOX) 和A2AR对抗剂 (SCH-58,261),以产生协同作用的抗瘤效应.

主要方法:

凝微球被设计为共载多克索鲁比辛 (DOX) 和含有A2AR对手SCH-58,261 (SLNP-SCH/DOX@MS) 的固体脂质纳米粒子.
微球的特点是尺寸,栓塞能力和药物释放概况.
在体外和体外研究评估了SLNP-SCH/DOX@MS对瘤细胞亡,树突细胞成熟,抗原呈现和免疫细胞功能的影响.

主要成果:

开发的SLNP-SCH/DOX@MS证明了有效的瘤血管栓塞和持续释放DOX和SCH-58,261.
通过促进树突细胞成熟和抗原呈现,治疗显著增强了瘤细胞亡和放大了免疫细胞死亡 (ICD).
SCH-58,261有效抵消TACE诱导的腺积累,并逆转免疫细胞功能障碍,包括CD8+ T细胞耗尽.

结论:

SLNP-SCH/DOX@MS的双重作用策略将ICD驱动的免疫刺激与腺通路阻塞进行协同作用,有效地重塑瘤微环境.
这种方法提供了一个有希望的解决方案,通过解决ICD和免疫抑制之间的平衡来提高TACE在不可切除的HCC的疗效.
该研究强调了将化疗与向免疫调节相结合的潜力,以改善癌症治疗结果.

关键词:

用药物装载的微球.肝细胞癌是肝细胞癌.免疫原性细胞死亡免疫治疗是一种免疫疗法.通过导管进行动脉化学栓塞.

更多相关视频

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.